1 - 7 October 2016
These are links to news stories from the last week that may be of interest to people in the UK. The link beneath each item will take you to the original story.
Please note that the MS Trust did not write the original items and does not endorse their content nor any claims made in them.
To keep up to date on all the latest news, views and research on multiple sclerosis, sign up for Open Door, our free newsletter or regular email alerts
The government have announced that they are to scrap reassessment of people claiming ESA (Employment Support Allowance) if they have a condition that is unlikely to have improved. The Work and Pensions Secretary said, "constant reassessment is pointless and increases stress and anxiety levels.”
MS Trust link: Benefits
NICE turns down daclizumab
NICE's initial recommendation is that daclizumab (Zinbryta) is not recommended for treating relapsing forms of MS. The decision, which affects England and Wales, is open for consultation until 21 October
MS Trust link: NICE says no to daclizumab (Zinbryta) - MS Trust news item (3 October)
Tysabri vs Gilenya comparison
Research that compared three previous clinical studies found that Tysabri (natalizumab) was associated with a lower relapse rate and better chance of NEDA (no evidence of disease activity) than Gilenya (fingolimod), though there was no difference on disease progression. Comparisons from five observational studies found the two drugs had a similar effect on relapse rate and disability progression, but people on Tysabri were more likely to be remain relapse-free after two years.
Source: MS News Today
MS Trust link: MS Decisions - a guide to the disease modifying drugs for relapsing MS